Résultats de la recherche

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...